Stay up to date on all things colon cancer. Sign up and we’ll send you the latest news, resources, scientific breakthroughs, events, tips, and much more.

Share this post on your profile with a comment of your own:

Successfully Shared!

View on my Profile

Young-Onset Microsatellite-Stable Colorectal Cancer

November 21, 2019


The goal of this laboratory research study is to learn more about genetic factors that may influence the risk for developing colorectal cancer at a young age. This study involves participants answering a questionnaire at the beginning of the trial and then again once a year for five years, and providing one blood or saliva sample.


Study Information

This is an observational study with approximately 1000 participants. It began in June 2012 and is estimated to be completed by June 2023.


Inclusion Criteria


  • MDACC patients who have adenocarcinoma of the colon or rectum, diagnosed between ages 18 through 50 (young-onset), or diagnosed at age 65 or older (later-onset), who had microsatellite status testing (by either immunohistochemistry or PCR testing or germline testing or a combination thereof).
  • Patient must have sufficient command of the English language and mental capacity to provide consent.


Family members who meet the following criteria will be eligible:

  • Be a parent, sibling or child (first degree blood relative) of a registered MDACC patient meeting eligibility criteria above.
  • Have sufficient command of the English language and mental capacity to provide consent.
  • Family member must be at least 18 years of age at the time of study registration.


Exclusion Criteria


  • Patient must NOT have known or suspected clinical diagnosis of a hereditary polyposis syndrome including hereditary adenomatous polyposis syndromes, hereditary nonadenomatous polyposis syndromes, and hereditary nonpolyposis syndromes.
  • Patient’s adenocarcinoma must NOT be microsatellite high or unstable (defined by loss of expression of at least one DNA mismatch repair genes MLH1, MSH2, MSH6, PMS2 by immunohistochemistry, and/or >30% allelic shift by microsatellite PCR testing).
  • Patient must NOT have a known germline mutation in DNA mismatch repair genes (MLH1, MSH2, MSH6, PMS2), APC, or MYH genes.



This study is taking place at the University of Texas MD Anderson Cancer Center, Houston, Texas, United States, 77030. For further information please contact Yi-Qian N. You, MD on 713-792-6940 or at



This study is sponsored by the M.D. Anderson Cancer Center, with Yi-Qian N. You, MD as the Principal Investigator.

Clinical Trials

View All Clinical Trials

DC Vaccine in Colorectal Cancer

This study is assessing the safety, tolerability and immune response rate the of mDC3 vaccine in patients with colorectal cancer.

Diet Modulation of Bacterial Sulfur and Bile Acid Metabolism and Colon Cancer Risk

This diet-intervention trial focuses on African American subjects who are at higher risk for developing colorectal cancer (CRC). Two diets, one…

Green Tea and Milk Thistle to Colorectal Cancer Patients

Colorectal cancer is the third most common form of cancer found in the United States, and surgical resection (removal) provides the best chance for…

Participatory Research to Advance Colon Cancer Prevention

The goal of this study is to test strategies to raise rates of colorectal cancer screening among the Latino population. This study will be split…

Reducing Rural Colon Cancer Disparities

This study is exploring the difference in outcomes for cancer patients in rural vs. urban areas. Southern Illinois will be used as the prime…

PalloV-CC in Colon Cancer

This study is looking at the effects of the PalloV CC vaccination on patients with colon cancer. The primary goals are to understand the safety of…

Exercise And Colon Cancer Treatment

This study is looking at how exercise may prevent the recurrence of colon cancer in patients who have completed their treatment. The primary…

Niclosamide in Patients With Resectable Colon Cancer

This study is examining the safety of the drug Niclosamide in patients with colon cancer that are undergoing primary resection (cutting out) of…

Send this to a friend